Hewitt, the world's leading human resources management consulting and service outsourcing company, recently released the 2009 China Market Medicine and Medical Device Industry Salary and Benefits Evaluation Report (hereinafter referred to as the “Hantwet Reportâ€), indicating that the pharmaceutical and medical device industries were affected by the financial crisis. Smaller. According to statistics, by the end of this year, the top ten foreign-funded pharmaceutical companies had a total of 3,000 hollow jobs.
The salary increase is higher than the overall level. The job-hopping rate is still high.
According to the Hewitt report, the overall wage growth rate of the pharmaceutical industry (non-manufacturing industry) in China in 2009 was about 9.09%, and the salary increases of professionals, senior professionals, middle managers and senior managers were 9.16% and 9.31% respectively. , 9.39% and 9.54%. The overall wage growth rate of the medical device industry (non-manufacturing industry) was 8.85%, and the salary increases of professionals, senior professionals, middle managers and senior managers were 8.54%, 9.13%, 8.27% and 8.22%, respectively.
In 2009, the active turnover rate of employees in the pharmaceutical market (non-manufacturing industry) in China reached 17.3% (15.2% in 2008); the average employee turnover rate in the medical device industry (non-manufacturing industry) reached 10.5% (in 2008). 13.6%). This shows that the demand for talents in the medical and medical device industry is still very strong, and the talent market is highly competitive.
Pharmaceutical consumption accelerates, China's market becomes a global highlight
Pharmaceutical consumption is a rigid consumption, although the decline in purchasing power will theoretically have a certain impact on drug consumption, but the rising coverage of medical insurance has offset this negative impact to some extent. Consumers of high-end drugs are also relatively fixed. Foreign employees, senior executives and state cadres are still major consumers, and China's pharmaceutical consumption as a whole is accelerating.
China is the fastest-growing country in developing countries. It is estimated that by 2010, the proportion of elderly people over 65 will reach 8.4%, and in 2040 this ratio will exceed 20%. From 2008 to 2020, the amount of universal health insurance and insurance will be gradually improved, and the development potential of the Chinese pharmaceutical market is huge. The top executives of many foreign-funded enterprises such as Novartis, Merck, Merck, Eli Lilly and Schering-Plough frequently visited China during the global economic downturn, which also shows that the Chinese market has become a global highlight.
Hewitt looks forward to the talent trend of the pharmaceutical industry
The Hewitt report also shows that as many medical and medical device R&D centers have fought in the Chinese market, the shortage of technical talents in foreign languages ​​is obvious, and the demand for R&D talents and recruitment has become a hot spot. At the same time, in order to attract more talents to return to China, more and more R&D centers have formulated corresponding welfare policies such as child education and supplementary pension.
With China's economic development, the establishment of a network of medical security systems, the depth of coverage continues to expand, and the per capita drug expenditure will also increase. The scale of China's foreign-invested pharmaceutical market will still maintain double-digit growth. Hewitt's experts believe that when major pharmaceutical companies are ready to work hard, they will strive to build a unique employer brand, accurately locate compensation-oriented companies, and provide personalized services such as supplementary housing, menu-based benefits, and flexible working hours. Welfare policy is an effective means of retaining core talent.
We have Oxytocin Injection and Cloprostenol Sodium Injection solve animals' parturition problems. Oxytocin Injection stimulates the uterus and strengthens the contraction of the uterine smooth muscle. Cloprostenol Sodium Injection subsides corpus luteum and stimulates uterine smooth muscle contraction and cervical relaxation.
Parturition Medicine,Cloprostenol Sodium for Injection,Cloprostenol Sodium Injection,Vet Hormone Medicine
Jiangxi Institute of Biological Products Inc. , https://www.jxinstitute.com